Worldwide, almost 314,000 women are diagnosed with ovarian cancer, and more than 207,000 die from this disease, making it the deadliest among gynecological cancers, with a 5-year survival rate of less than 35%. When detected at an early stage, the survival is over 90%.
iLoF is determined to address this late-stage detection issue by collecting patterns of serum samples from women with ovarian malignant and benign tumors, helping in clinical decisions and discriminating malignancy preoperatively. Implementing this screening model will significantly impact disease outcomes. iLoF is also committed to revolutionize early detection of ovarian cancer.
Partner
